Download Duopa

Special points of interest

th
Du op a ( Du e oh p ah )

January 12 2015 FDA approved the release of Duopa
D UO P A w as ap p r o ved

Used for the treatment of: Motor fluctuations in patients with
b y th e F D A as an or p h a n

advanced Parkinson's disease.
Dosage: Enteral Suspension.
d r u g , a d es i gn at ion

Marketing Information from Manufacturer:
gr an ted to p r od u ct s
Duopa (Due oh pah) provides patients with the same active
ingredients as orally-administered carbidopa and levodopa
immediate release, but is delivered in a suspension that goes
directly into the small intestine via a tube. "There is unmet need for
treatment options for patients with advanced Parkinson's disease.
As the disease advances, it can be difficult to control motor
features," Dr. Olanow said in the company statement. "In clinical
trials, Duopa was shown to significantly reduce the amount of off
time (per 16 waking hours) advanced Parkinson's disease patients
experienced.”
Benefits and Concerns of the Drug: This drug is targeted for a
limited number of Parkinson’s patients and its administration
through an enteral tube further limits potential candidates for
Duopa. Prior Authorization for coverage is suggested to assure only
properly qualified and prepared patients receive coverage for the
drug.
Coverage Recommendations: These recommendations are
available to IPC/EvergreenRx clients from their Account Manager or
Clinical Pharmacist.
in ten d ed for th e


Please contact us with any questions or comments

tr eatm en t o f r ar e
d is e a se s.

Gen er ic N am e
car b id op a an d le vod op a
T 636.614.1344
www.ipc-inc.com
A Brown & Brown company